摘要
肝细胞癌(hepatocellular carcinoma,HCC)是中国最常见恶性肿瘤之一,门静脉癌栓(portal vein tumor thrombosis,PVTT)是HCC常见的临床表现及独立预后危险因素。不同国家或地区HCC指南推荐的PVTT治疗方案也有很大差异。欧洲和美国推荐索拉非尼作为一线治疗方法,中国及日本近年来推荐外科手术治疗,但目前尚无国际公认的PVTT诊断和治疗的共识或指南。近年来,HCC合并PVTT患者有了更多的治疗方法。通过更新总结临床医生对HCC合并PVTT的手术、放化疗等治疗方案和多学科联合治疗等共识声明,制订合理的治疗方案,以提高患者的生活质量,延长总生存期及减少并发症。
Hepatocellular carcinoma(HCC)is one of the most common malignancies in China,and portal vein tumor thrombosis(PVTT)is a common clinical manifestation and an independent prognostic risk factor for HCC.The treatment options for PVTT recommended by HCC guidelines vary greatly from country to country or region to region.In Europe and the United States,sorafenib is recommended as the first-line treatment,while in China and Japan,surgical treatment has been recommended in recent years,but there is no internationally accepted consensus or guideline for the diagnosis and treatment of PVTT.In recent years,more treatment options have become available for patients with HCC combined with PVTT.By updating and summarizing clinicians’therapeutic protocols such as surgery and radiotherapy for HCC combined with PVTT,and consensus statements such as multidisciplinary combination therapy,reasonable treatment plans are developed to improve patients’quality of life,prolong overall survival,and reduce complications.
作者
王木子(综述)
刘宏(审校)
WANG Muzi;LIU Hong(First Clinical Medical School,Shanxi Medical University,Taiyuan 030001;Hepatobiliary Pancreatic Surgery and Liver Transplantation Center,First Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处
《临床与病理杂志》
CAS
2023年第4期827-835,共9页
Journal of Clinical and Pathological Research
基金
山西省自然科学基金(201901D111350)。
关键词
肝细胞癌
门静脉癌栓
外科治疗
系统疗法
放射治疗
hepatocellular carcinoma
portal vein tumor thrombosis
surgical treatment
systemic therapy
radiotherapy
